🇺🇸 FDA
Pipeline program

PRAX-562

PRAX-562-221

Phase 3 small_molecule active

Quick answer

PRAX-562 for SCN2A Encephalopathy is a Phase 3 program (small_molecule) at PRECISION BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
PRECISION BIOSCIENCES INC
Indication
SCN2A Encephalopathy
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials